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ABSTRACT  39 
Sex hormone concentrations of eumenorrheic females typically fluctuate across the 40 
menstrual cycle and can affect neural function such that oestrogen has neuro-excitatory 41 
effects, and progesterone induces inhibition. However, the effects of these changes on 42 
corticospinal and intracortical circuitry, and the motor performance of the knee-43 
extensors, are unknown. The present two-part investigation aimed to i) determine the 44 
measurement error of an exercise task, transcranial magnetic stimulation (TMS) and 45 
motor nerve stimulation (MNS) derived responses in females ingesting a monophasic 46 
oral contraceptive pill (hormonally-constant), and ii) investigate whether these 47 
measures were modulated by menstrual cycle phase (MCP), by examining them before 48 
and after an intermittent isometric fatiguing task (60% of maximal voluntary contraction, 49 
MVC) with the knee-extensors until task failure in eumenorrheic females on days 2, 14, 50 
and 21 of the menstrual cycle. The repeatability of neuromuscular measures at baseline 51 
and fatigability ranged between moderate-excellent in females taking the oral 52 
contraceptive pill. Maximal voluntary contraction was not affected by MCP (P=0.790). 53 
Voluntary activation (MNS and TMS) peaked on day 14 (P=0.007 and 0.008, respectively). 54 
Whilst corticospinal excitability was unchanged, short-interval intracortical inhibition 55 
was greatest on day 21 compared to days 14 and 2 (P=0.001). Additionally, time to task 56 
failure was longer on day 21 compared to both days 14 and 2 (24 and 36%, respectively; 57 
P=0.030). The observed changes were larger than the associated measurement errors. 58 
These data demonstrate that neuromuscular function and fatigability of the knee-59 
extensors varies across the menstrual cycle, and may influence exercise performance 60 
involving locomotor muscles. 61 
 62 
 63 
 64 
 65 
 66 
 67 
 68 
 69 
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NEW AND NOTEWORTHY 72 
The present two-part study first demonstrated the repeatability of transcranial magnetic 73 
stimulation and electrical motor nerve stimulation evoked variables in a hormonally-74 
constant female population. Subsequently, it was demonstrated that the eumenorrheic 75 
menstrual cycle affects neuromuscular function. Changing concentrations of neuroactive 76 
hormones corresponded with greater voluntary activation on day 14, greater 77 
intracortical inhibition on day 21, and lowest fatigability on day 21. These alterations of 78 
knee extensor neuromuscular function have implications for locomotor activities. 79 
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INTRODUCTION 80 
The cyclical changes in concentrations of multiple sex hormones, including oestrogen and 81 
progesterone (55), across the eumenorrheic menstrual cycle can affect central nervous 82 
system (CNS) function due to their ability to cross the blood-brain barrier (62). In vitro 83 
models have shown direct evidence for the effect of sex hormones on neuronal function. 84 
For instance, oestradiol (an oestrogenic steroid hormone) binds to oestrogen receptor α 85 
(ER-α) sites on γ-aminobutyric acid (GABA) mediated neurons, causing an attenuation in 86 
GABA synthesis and release (54, 70). Additionally, oestrogen potentiates the effects of 87 
excitatory glutamatergic (both NMDA and non-NMDA) receptors (61), resulting in a net 88 
excitatory effect. Additionally, oestrogen has been shown to decrease firing thresholds 89 
and increase discharge frequency of cerebral neurons (58, 72). On the contrary, 90 
progesterone has a net inhibitory effect on the nervous system, as the activity and effects 91 
of GABA are potentiated, leading to decreased neuronal discharge rate (60) and increased 92 
inhibition of pyramidal neurons in rats (37). Some evidence also suggests that the 93 
presence of progesterone directly antagonises estrogenic actions by lowering the 94 
available ER-α and -β receptor numbers on various sites of  neuronal cells (47).  Indeed, 95 
as Smith and Woolley (61) outlined, the neurosteroidal actions of hormones act upon the 96 
neurotransmitter receptors. Thus, given GABAergic and glutamatergic synapses are 97 
located within the motor cortex (43), a hormonal effect would be expected 98 
 99 
The differential effect of oestrogen and progesterone concentrations on indices of 100 
nervous system excitability have also been established in humans.  Transcranial magnetic 101 
stimulation (TMS) studies show increased intracortical excitability and reduced 102 
intracortical inhibition in the late-follicular phase, when oestradiol concentration is high 103 
and progesterone low (56, 57), substantiating the alterations seen in the aforementioned 104 
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in vitro studies. While these in vivo studies show clear changes in human CNS function, 105 
they were conducted in the resting upper limbs, specifically in hand muscles associated 106 
with fine motor control. However, properties of intracortical and corticospinal circuits 107 
vary between upper and lower limb projections (7, 15). Thus, the menstrual cycle 108 
associated modulations in neural function of a small, upper limb muscle group cannot be 109 
extrapolated to larger, lower limb muscle groups. Understanding how the menstrual 110 
cycle affects the neural control of large locomotor muscle groups has significant 111 
implications for everyday locomotive tasks, injury rehabilitation, and athletic 112 
performance. For instance, neuroplasticity following stroke (17), and strength training 113 
(71) are influenced by GABAergic inhibition. 114 
 115 
To date, there is minimal research investigating menstrual cycle induced changes in 116 
nervous system and motor function of the knee extensors (KE). Previous studies 117 
investigating motor function, such as the ability to produce maximum voluntary 118 
contraction force (MVC), are equivocal, with studies showing 8-23% greater maximal 119 
force with the KE mid-cycle (4, 53, 64). Multiple studies however, report no difference in 120 
maximal strength (20, 24, 40, 46). The studies that have shown changes in maximal 121 
strength have suggested that mechanisms such as motor unit firing rates (65) and 122 
intracortical excitability (56, 57) could be contributing factors. However, the proposed 123 
mechanistic factors, and the neuromuscular response (e.g. MVC), have not been 124 
concurrently studied. Voluntary activation (VA) of the quadriceps has been assessed 125 
using motor nerve stimulation twice with no menstrual cycle effect shown (40, 46). 126 
However, as it is thought  that the assessment of VA using TMS (VATMS) reflects the ability 127 
of the motor cortex to activate the motor units within the target muscle group (68), if 128 
supraspinal properties are modulated by the menstrual cycle (i.e. 56, 57), VATMS could 129 
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provide a more appropriate measure to discern whether the ability to voluntarily activate 130 
the KE is affected. 131 
 132 
Other aspects of motor performance, such as performance fatigability (38), have also 133 
been studied throughout the menstrual cycle with inconclusive results. Sarwar et al. (53) 134 
showed that the KE of eumenorrheic females were less fatigable in the luteal phase during 135 
an electrically stimulated isometric fatiguing protocol. However, this finding has not been 136 
corroborated with dynamic, voluntary contractions performed with the KE (21, 40). 137 
Additionally, none of the aforementioned studies were open-ended, with a fatigue index 138 
calculated after a set amount of time/contractions. Thus, due to the causes of fatigability 139 
being task specific (66), discrepancies in the aforementioned investigations could be due 140 
to the differences in fatiguing protocols used and their respective limiting factors.  141 
 142 
The effect of hormonal fluctuations on neuromuscular function and fatigability of the KE 143 
remains unclear. Conflicting literature exists for the majority of neuromuscular variables, 144 
despite a rationale for change based on neuroendocrine and upper-limb studies. The 145 
inclusion of statistical measures of error are recommended for investigations utilising 146 
methods of neurostimulation to inform the contribution of random variation to any 147 
modifications in neuromuscular function (29). Therefore, the present investigation 148 
recruited a population of monophasic oral contraceptive (mOCP) users to discern test-149 
retest repeatability of neuromuscular function measures without the influence of 150 
endogenous hormones (Study A). The consistent dosage of exogenous oestrogen and 151 
progesterone in the mOCP precludes ovulation (28), creating a physiological 152 
environment in which the effects of endogenous hormones are negated. Thereafter, Study 153 
B aimed to investigate KE neuromuscular function and fatigability across the menstrual 154 
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cycle. It was hypothesised that when oestrogen levels increased (and progesterone 155 
remained low) from day 2 to 14, maximum force production would concomitantly rise, 156 
alongside a reduction in intracortical inhibition and an increase in VA. Secondly, it was 157 
hypothesized that the rise in progesterone from day 14 to 21 would occur alongside a 158 
reversal in these changes, and improved time to task failure (TTF). 159 
  160 
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METHODS 161 
Ethical Approval 162 
The study received institutional ethical approval from the Northumbria University Health 163 
and Life Sciences Research Ethics Committee (HLSPA301116) and was conducted 164 
according to all aspects of the Declaration of Helsinki, apart from registration in a 165 
database. Participants provided written, informed consent to volunteer for the study 166 
 167 
Participants 168 
A total of 30 participants volunteered to participate in the study. Fifteen mOCP users (age: 169 
23 ± 2 years; stature: 170 ± 6 cm; mass: 70.6 ± 8.5 kg) and fifteen eumenorrheic females 170 
(age: 25 ± 4 years; stature: 169 ± 6 cm; mass: 68.3 ± 7.8 kg; mean cycle duration: 29 ± 3 171 
days, range: 24-34 days). The mOCPs reported taking an mOCP for at least 6 months as 172 
prescribed (i.e. a seven-day break after every 21-day pill consumption period), whereas 173 
eumenorrheic females reported having regular cycles without using any form of 174 
hormonal contraceptives for at least six months. A full list of the mOCPs taken by 175 
participants is presented in Table 1. Participants arrived at the laboratory rested and 176 
hydrated, with strenuous physical activity avoided for 48 hours, and caffeine and alcohol 177 
prohibited for 24 hours.  178 
 179 
TABLE 1 HERE 180 
 181 
Experimental Design 182 
Study A 183 
Oral contraceptive users visited the laboratory three times, completing a familiarisation 184 
and two experimental visits. Experimental visits were completed during the final 14 days 185 
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of the pill cycle, with a minimum of 48 h between visits to allow recovery (13). The visits 186 
were identical to those described below for Study B, however, blood sampling was not 187 
performed as it is established that endogenous hormone concentrations do not fluctuate 188 
throughout the consumption phase of the mOCP cycle (10). 189 
 190 
Study B 191 
Eumenorrheic females visited the laboratory four times, completing a familiarisation 192 
session prior to three experimental visits. Participants completed experimental visits on 193 
days 2 (D2, Early-follicular), 14 (D14, Late-follicular), and 21 (D21, Mid-luteal) of the 194 
menstrual cycle. Testing days were counted from the onset of menstruation and, to verify 195 
menstrual cycle phase, fasted venous blood samples were taken between the hours of 196 
0600 – 0900 on testing days to analyse serum oestradiol and progesterone 197 
concentrations. The order of visits was pseudorandomized and counterbalanced to 198 
minimize order effects, with five participants beginning on each testing day (D2, D14 or 199 
D21). All testing visits occurred within the same menstrual cycle (order: D2, D14, D21), 200 
or two consecutive cycles (order: D14, D21, D2 or D21, D2, D14). Experimental visits 201 
consisted of a baseline neuromuscular assessment, intermittent, isometric contractions 202 
at 60% MVC until task failure, followed immediately by a post-task neuromuscular 203 
assessment. The intensity for the fatiguing task was likely far greater than the critical 204 
torque (~30% MVC [12]), and therefore an unsustainable intensity, with task failure 205 
attributable to decrements in neuromuscular function (1, 11). 206 
 207 
Experimental Procedures 208 
For Study B, upon arriving between the hours of 0600 – 0900, fasted venous blood 209 
samples were taken following 10 minutes of seated rest. Participants were then 210 
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instructed to consume a typical breakfast and return to the laboratory at their designated 211 
testing time. The breakfast and time of testing were replicated (± 1 hour) for each 212 
experimental visit to control for diurnal variations in corticospinal excitability and 213 
maximal force production (63). Time of testing was also controlled for in Study A, with 214 
participants consuming the mOCP a constant time before trials in order to standardise 215 
circulating exogenous hormone concentrations between visits. In both studies, 216 
experimental sessions began with participants completing a standardised voluntary 217 
isometric contraction warm up (2 × contractions at 25, 50, and 75% perceived maximal 218 
effort) followed by a baseline neuromuscular assessment (described below). The 219 
fatiguing task involved sets of intermittent isometric contractions (3 s contraction, 2 s 220 
rest at 60% MVC) to task failure. Contractions were paced with an audible metronome to 221 
ensure the duty cycle was maintained. One set was defined as 11 submaximal 222 
contractions followed by a 3 s MVC with motor nerve stimulation (MNS) delivered at the 223 
peak force and 2 s post, lasting one minute. Task failure was defined as an inability to 224 
reach the target force three times at any stage of the protocol. Rating of perceived 225 
exertion (RPE; 6) was recorded using a 6-20 scale following each MVC throughout the 226 
fatiguing task. Real-time visual force feedback using target forces set as percentages of 227 
maximum force was provided to participants on a computer screen to aid a constant force 228 
level. The post-task neuromuscular assessment began immediately following task failure. 229 
 230 
Neuromuscular Assessments 231 
Measures of neuromuscular function were assessed pre- and post- exercise with MNS of 232 
the femoral nerve, and TMS of the contralateral motor cortex at rest and during voluntary 233 
contractions of the right knee-extensors. Pre-exercise neuromuscular assessments began 234 
with two practice MVCs to ensure potentiation of subsequent evoked measures, followed 235 
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by three ~3 s MVCs, all separated by 30 s. During these 3 MVCs, MNS was delivered when 236 
peak force plateaued, and then ~2 s after the MVC to measure voluntary activation 237 
(VAMNS) and potentiated twitch amplitude (Qtw.pot) of the knee-extensors. Single-pulse 238 
TMS was subsequently delivered during two sets of five 3-5 s contractions at 100, 87.5, 239 
75, 62.5 and 50% MVC, with 5 s rest between contractions and 10 s rest between sets, to 240 
determine VATMS  (19). The TMS silent period (SP) was determined during the 50% MVC 241 
contraction of each set. Participants were instructed to maintain a constant force on the 242 
guideline and “push through the stimulation” (52). Finally, ten single- and ten paired-243 
pulse TMS stimulations were delivered during a 10% MVC contraction in an alternate 244 
order to determine corticospinal excitability and short-interval cortical inhibition (SICI), 245 
respectively. The neuromuscular assessment was repeated immediately post-exercise. 246 
Measures of neuromuscular function (MVC, Qtw.pot, VAMNS) were measured within 30 s of 247 
task failure, and VATMS measured within 2-2.5 minutes, in an attempt to minimise the 248 
dissipation of fatigue, however it is possible that the sensitivity of these measures was 249 
compromised due to the rapid recovery of central fatigue post-exercise (32). 250 
 251 
Force and Electromyographical Recordings 252 
During assessments of neuromuscular function and fatiguing tasks, participants sat on a 253 
custom-built chair with knee and hip angles kept constant (both 90° flexion). A calibrated 254 
load cell (MuscleLab force sensor 300, Ergotest technology, Norway) was attached via a 255 
non-compliant cuff positioned 2 cm superior to the ankle malleoli on the participants’ 256 
right leg, to measure knee extensor force (N). Surface Ag/AgCl electrodes (Kendall 257 
H87PG/F; Covidien, Mansfield, MA) were placed over the rectus femoris (RF), and biceps 258 
femoris (BF) with a 2 cm inter-electrode distance, to record the compound muscle action 259 
potential (M-wave) elicited by the electrical stimulation of the femoral nerve, the MEP 260 
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elicited by TMS, and the root-mean-square amplitude during isometric contractions 261 
(rmsEMG). Electrode placement was consistent with SENIAM guidelines (35), and a 262 
reference electrode was placed over the patella. Prior to placement, the skin-electrode 263 
contact area was cleaned using a 70% IPA alcohol wipe (FastAid, Robinson Healthcare, 264 
Worksop, UK). Signals were amplified: gain ×1000 for EMG and ×300 for force (CED 1902; 265 
Cambridge Electronic Design, Cambridge, UK), bandpass filtered (EMG only: 20–2000 266 
Hz), digitized (5 kHz; CED 1401, Cambridge Electronic Design), and analysed offline 267 
(Spike2 v8, Cambridge Electronic Design). 268 
 269 
Motor Nerve Stimulation 270 
Single electrical stimuli (200 µs duration) were delivered to the right femoral nerve using 271 
a constant current stimulator (DS7AH Digitimer Ltd, Welwyn Garden City, UK) via 272 
adhesive surface electrodes (CF3200; Nidd Valley Medical Ltd., Harrogate, UK). The 273 
cathode was placed over the nerve, high in the femoral triangle, in the position that 274 
elicited the greatest twitch amplitude (Qtw) and M-wave in the RF at rest. The anode was 275 
placed halfway between the greater trochanter and iliac crest. Optimum stimulus 276 
intensity was determined as the minimum current that elicited maximum values of Qtw 277 
and M-wave (Mmax) at rest. To ensure a supramaximal stimulus, the optimum stimulus 278 
intensity was increased by 30% and was not different between trials in either study (A: 279 
230 ± 61 vs. 241 ± 65 mA, P = 0.271; B: 233 ± 72, 244 ± 68, and 262 ± 67 mA, P = 0.125). 280 
 281 
Transcranial Magnetic Stimulation 282 
Single and paired pulse stimuli (1 ms duration) were delivered to the contralateral (left) 283 
motor cortex via a concave double cone coil (110 mm diameter, maximum output 1.4 T) 284 
powered by two linked monopulse stimulators (Magstim Bistim and Magstim200, The 285 
13 
 
Magstim Company, Whitland, UK). Optimal coil placement was determined as the 286 
position that elicited the greatest RF motor evoked potential (MEP) with concomitant 287 
smallest antagonist (BF) MEP during a 10% MVC at 50-70% stimulator output. This 288 
position was marked on the scalp with indelible marker to ensure consistent placement 289 
during trials. Stimulator intensity for VATMS was determined as the intensity that elicited 290 
the greatest superimposed twitch (SIT) during a contraction at 50% MVC. Stimulator 291 
intensity was increased in 5% intervals from 50% stimulator output and two stimuli 292 
were delivered during a ~5 s contraction, with the mean of two SITs recorded (9, 18). 293 
Mean stimulator intensity was not different between trials in either study (A: 67 ± 10 vs. 294 
66 ± 10%, P = 0.737; B: 63 ± 10, 63 ± 11, and 63 ± 12%, P = 0.984). The stimulator output 295 
activated a large proportion of the KE motoneuron pool at baseline in each experimental 296 
visit with no difference between trials in Study A (69 ± 35 vs. 68 ± 36% Mmax amplitude, 297 
P = 0.916) or Study B (61 ± 17; 57 ± 17; 55 ± 14% Mmax amplitude; P = 0.788). Small co-298 
activation of the antagonist muscle (BF) was observed in response to TMS and did not 299 
differ between trials in Study A (0.60 ± 0.37 vs. 0.72 ± 0.53 mV, P = 0.106) or Study B (0.53 300 
± 0.39, 0.71 ± 0.42 and 0.60 ± 0.34 mV, P = 0.211). 301 
 302 
Active motor threshold (aMT) was determined as the stimulator intensity that elicited a 303 
MEP of > 200 µV in three out of five stimulations during a 10% MVC contraction. 304 
Stimulator intensity was increased in 5% steps from 35% of stimulator output until a 305 
consistent MEP amplitude >200 μV was found. Thereafter, stimulus intensity was 306 
reduced in 1% steps until the lowest intensity to elicit a MEP of >200 μV was found. aMT 307 
was not different on any testing visit in Study A (40 ± 6 vs. 40 ± 7%, P = 0.746) or Study B 308 
(43 ± 9, 42 ± 8, and 43 ± 9%, P = 0.874). SICI was assessed with ten paired and ten single 309 
pulse stimulations delivered. Paired-pulse TMS consisted of a conditioning pulse at 70% 310 
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of aMT, and a test pulse at 120% aMT, with an inter-stimulus interval of 2 ms. All stimuli 311 
were delivered during a 10% contraction. This paradigm has previously been 312 
demonstrated as the optimal configuration for eliciting SICI in the KE (8), and has been 313 
used previously in our laboratory in male populations (31). Two sets of 10 stimuli were 314 
used, with a 10 s rest between contractions. 315 
 316 
Blood Sampling and Hormone Analysis (Study B only) 317 
Venous blood sampling was performed on the morning of each testing session. A 10 mL 318 
blood sample was drawn from an antecubital vein into a silica coated tube by a trained 319 
phlebotomist, then left upright for 15 minutes to coagulate before centrifuging. Samples 320 
were centrifuged at 2,500 rpm for 10 minutes at room temperature (Allegra-X22R, 321 
Beckman Coulter, USA). Using a 500-1000 µl pipette, the supernatant serum was separated 322 
into three aliquots (~1000 µl each) and stored at −80°C until oestradiol and progesterone 323 
analysis were performed. Total concentrations of 17-β oestradiol and progesterone were 324 
measured in duplicate using hormone-specific enzyme-linked immunoassay kits 325 
(Cayman Chemical, Ann Arbor, MI). All samples were analysed using the ELISA technique 326 
with absorbance detection (wavelength 405 nm). The minimal oestradiol and 327 
progesterone detection was 15 pg/ml and 7.5 pg/mL, respectively. To calculate 17-β 328 
oestradiol and progesterone levels, a standard curve was plotted using eight standards 329 
against their absorbance. Using the mean absorbance from the duplicate of each sample, 330 
the concentration of the sample was interpolated directly from the standard curve. The 331 
coefficients of variation (CV) for the ELISA kits, as provided by the manufacturer, were 8-332 
12% for 17-β oestradiol, and 5-8% for progesterone. In one instance, the CV of a duplicate 333 
sample exceeded the manufacturer’s CV due to an excessively high (non-physiological) 334 
reading in one well. Therefore, the lower of the two was used for data analysis. 335 
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Participants’ hormonal profiles were deemed ‘acceptable’ when a peak in progesterone 336 
concentration was observed during the luteal phase (D21) and an increase in 17-β 337 
oestradiol was observed from D2 to D14. If neither peak was observed, then participants 338 
were deemed anovulatory and excluded from further analyses.  339 
 340 
Data Analysis 341 
Voluntary activation using motor nerve stimulation was determined using the ITT (48) 342 
by comparing the amplitude of the superimposed twitch (SIT) with the amplitude of the 343 
potentiated resting twitch (Qtw.pot) using the following formula: VAMNS (%) = (1 – [SIT ÷ 344 
Qtw,pot]) × 100]. Voluntary activation using TMS was assessed during two sets of 345 
contractions at 100, 87.5, 75, 62.5 and 50% MVC (19). Single pulse TMS was delivered 346 
during each contraction, and the linear regression between SIT amplitude and 347 
contraction intensity was extrapolated to the y intercept to obtain an estimated resting 348 
twitch (ERT; 68) . In order to achieve significant linearity (P < 0.05), a total of 4 out of 300 349 
SITs across all trials in Study A were excluded (1.3%), which led to four regressions 350 
containing 9 data points rather than 10 (1 pre-exercise, 3 post-exercise). In Study B, six 351 
out of 870 SITs were excluded from all linear regressions (0.7%), meaning that there 352 
were 86 ten point regressions, three nine point regressions, and one eight point 353 
regression used to estimate resting twitches. Mean r2 values for ERTs in Study A were 354 
0.94 ± 0.04 pre exercise vs. 0.94 ± 0.04 post exercise, and in Study B were 0.92 ± 0.05 pre 355 
exercise, and 0.89 ± 0.07 post-exercise. The SIT during 100% MVC was compared with 356 
the ERT using the following formula: VATMS (%) = (1 – [SIT ÷ ERT]) × 100. SICI was 357 
quantified as the percentage ratio between the amplitude of conditioned MEPs to the 358 
amplitude of unconditioned MEPs. Corticospinal excitability was determined by 359 
expressing the mean MEP amplitude during the 10% MVC as a percentage of Mmax. The 360 
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root-mean-square of EMG activity (rmsEMG) was recorded during the middle 500 ms 361 
epoch of each 3 s contraction during the fatiguing task. rmsEMG was then expressed as a 362 
percentage of Mmax.  For the data presented as %TTF, the MVC, VAMNS, and Qtw.pot for the 363 
nearest minute during the fatiguing protocols were taken, and the average rmsEMG for 364 
the nearest full set of contractions to the target percentage (i.e. 25, 50, or 75% TTF) was 365 
taken, for 0 and 100% TTF, the first and last complete set was used. All data analysis was 366 
performed offline. In Study B, despite a rigorous familiarisation and verbal 367 
encouragement, one participant failed to maintain the intermittent contractions for the 368 
required 3 s during the fatiguing task, thus invalidating the TTF duration. Therefore, it 369 
was deemed appropriate to remove the participant’s TTF duration and post-trial 370 
neuromuscular assessment from further analysis (n = 14), however, baseline data was 371 
included for statistical analysis (n = 15). 372 
 373 
Statistical Analysis 374 
Data are presented as mean ± SD within the text and figures. Normal Gaussian 375 
distribution of data was confirmed using the Kolmogorov–Smirnov test. If a violation was 376 
detected, the data was logarithmically transformed. The alpha for all statistical tests was 377 
set at P ≤ 0.05. 378 
 379 
For Study A, between session and pre-post exercise differences were explored using two-380 
way (2 × 2) repeated measures ANOVAs, if assumptions of sphericity were violated, then 381 
the Greenhouse-Geisser correction was applied. If significant main or interaction effects 382 
were detected, Bonferroni-corrected post hoc tests were performed. For between session 383 
test-retest reliability multiple indices were calculated (paired samples t-tests, typical 384 
error, intraclass correlation coefficient, 2, 36) between the two time points. Within-385 
17 
 
subjects variation was calculated as the standard deviation of the mean differences 386 
divided by the square root of 2, and termed typical error (TE) throughout the manuscript. 387 
Typical error was expressed as absolute raw values and as a percentage of the mean 388 
(coefficient of variation, CV). Intraclass correlation coefficients (ICC3,1) were calculated 389 
according to Bland and Altman (5). ICC values were defined as follows: <0.5 = poor, 0.5-390 
0.75 = moderate, 0.75-0.9 = good, >0.9 = excellent (45). Due to the ceiling effect (i.e. all 391 
values grouped close to 100%) associated with VAMNS and VATMS, the ICCs were not 392 
calculated (16, 67). 393 
 394 
For study B, one-way repeated measures ANOVAs were run for all pre-exercise 395 
dependent variables to assess MCP changes in neuromuscular function and hormone 396 
concentrations. Sphericity was assessed using Mauchly’s test and if necessary, controlled 397 
using the Greenhouse-Geisser correction. Two-way repeated measures ANOVAs were 398 
run using pre and post exercise variables to obtain both fatigue, and MCP × fatigue 399 
interaction effects. To explore potential differences in the fatigue profiles of 400 
neuromuscular and perceptual variables, two-way repeated measures ANOVAs were run 401 
including data points from baseline, 25%, 50%, 75%, and 100% of TTF. Significant main 402 
and interaction effects were explored using Bonferroni-corrected tests. 403 
  404 
RESULTS 405 
Study A 406 
Exercise performance and pre-post exercise changes 407 
The TTF was not different between experimental visits (560 ± 275 s vs. 603 ± 357 s 408 
respectively, P = 0.314). When assessing exercise-induced changes in neuromuscular 409 
function, the two-way ANOVAs detected no between-trial differences in change scores 410 
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(trial × time interactions: P ≥ 0.331), therefore to assess the pre-post change, data from 411 
both visits were pooled. The MVC decreased pre-post exercise (time effect: 507 ± 95 vs. 412 
379 ± 85 N; F1,14 = 136.66, P < 0.001, η2 = 0.91). Similarly, indices of contractile function 413 
(Qtw.pot and ERT) decreased pre-post trial (Qtw.pot: 169 ± 24 vs. 109 ± 21 N; F1,14 = 92.61, P 414 
< 0.001, η2 = 0.87; ERT: 120 ± 36 vs. 93 ± 28 N; F1,14 = 19.07, P = 0.001, η2 = 0.56). Indices 415 
of VA also decreased pre-post trial: VAMNS (93.6 ± 3.2 vs. 85.1 ± 6.8%; F1,14 = 36.60, P < 416 
0.001, η2 = 0.72) and VATMS (94.6 ± 3.1 vs. 83.1 ± 10.6%; F1,14 = 20.82, P < 0.001, η2 = 0.60). 417 
Corticospinal excitability (MEP/Mmax) was not different pre-post exercise (P = 0.057). 418 
There were no changes in SICI pre-post exercise (80.8 ± 14.2 vs. 79.8 ± 13.9%, P = 0.667), 419 
whereas SP duration lengthened (189 ± 46 vs. 202 ± 50 ms, F1,14 = 5.49, P = 0.034, η2 = 420 
0.28). Lastly, Mmax was not different pre-post exercise (3.02 ± 1.19 vs. 2.81 ± 1.01 mV, P = 421 
0.362). 422 
 423 
TABLE 2 HERE 424 
 425 
Reliability of neuromuscular measures 426 
Pre-exercise data from mechanical variables (Table 2) showed good (ERT, and TTF) and 427 
excellent (MVC, and Qtw,pot) reliability. The TE and CV were also low for the majority of 428 
variables (CV ≤ 12.5%), except TTF (CV = 20.0%). Post-exercise reliability (Table 2) was 429 
weaker, but still interpreted as predominantly good (Qtw,pot, ERT) or excellent (MVC). 430 
These values were all poorer post-exercise; however, remained relatively low (CV ≤ 431 
14.9%). The relative reliability (ICCs) of the pre-post change was either moderate (MVC, 432 
ERT, VAMNS) or good (Qtw,pot), however there was a high degree of random error (CV 433 
range: 19.7 – 62.7%). 434 
 435 
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TABLE 3 HERE 436 
 437 
Surface EMG variables (Table 3) showed moderate (MEP/Mmax, SP) or good (SICI, Mmax) 438 
reliability pre-exercise, but with larger test-retest CVs than mechanical variables (range: 439 
9.2 – 30.1%). Post-exercise reliability was similar to pre- for most variables, with ICCs 440 
either moderate (MEP/Mmax, SP) or good (Mmax), and comparable CVs (range 13.0 – 441 
31.0%). Despite this, the post-exercise reliability of SICI was poor (ICC = 0.42), which was 442 
further supported by a significant bias between visits 1 and 2 (−9.1%, P = 0.031). When 443 
the pre-post change was significant for a variable, i.e. SP, the relative reliability of change 444 
value was deemed poor (ICC = 0.44), with a high degree of random error (CV: 155.1%). 445 
  446 
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Study B 447 
Hormonal Profiles 448 
 449 
TABLE 4 HERE 450 
 451 
Thirteen out of 15 participants presented a regular hormonal profile (see Table 4). Two 452 
participants had no increase in progesterone on D21; given the hypothesis that changing 453 
hormone concentrations would modulate neuromuscular function, and these 454 
participants did not exhibit any change in hormone concentrations, they were excluded 455 
from further statistical analyses. The repeated measures ANOVAs showed an effect of 456 
MCP on 17-β oestradiol (F1.4,19.5 = 3.55, P = 0.040, ηp2 =0.18) and progesterone 457 
concentration (F=1.0,14.1 = 8.35, P = 0.012, ηp2 =0.37). Post hoc tests revealed that 17-β 458 
oestradiol concentrations were greater on D14 compared to D2 (P = 0.033), and greater 459 
on D21 than D2 (P = 0.029). Progesterone was greater on D21 than D2 and D14 (P = 0.011, 460 
and 0.012, respectively). 461 
 462 
Baseline Neuromuscular Function 463 
 464 
FIGURE 1 HERE 465 
 466 
MVC force was unaffected by MCP (Figure 1A, F1.4,16.8= 0.15, P = 0.790, ηp2 = 0.01). 467 
Potentiated twitch force was also unchanged (Figure 1B, F2,24 = 0.25, P = 0.782, ηp2 = 0.02); 468 
however, the SIT elicited by MNS was affected by MCP (F2,28 = 3.69, P = 0.040, ηp2 = 0.24), 469 
with greater SITs on D14 compared to D2 (mean difference: 2 N, P = 0.031). The reduced 470 
SIT on D14 meant that VAMNS was affected by MCP (Figure 1C, F2,28 = 9.23, P = 0.001, ηp2 471 
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= 0.44) with post hoc tests showing greater VAMNS on D14 compared to D2 (mean 472 
difference: 1.9%, P = 0.007), however, there was no difference between D14 and D21 473 
(mean difference: 1.0%, P = 0.059). VATMS was also affected by MCP (Figure 1D, F2,28 = 474 
5.89, P = 0.008, ηp2 = 0.33) with greater values on D14 compared to D21 (mean difference: 475 
3.0%, P = 0.016), however, D14 and D2 were not different (mean difference: 2.5%, P = 476 
0.080). Despite the change in VATMS, neither of its constituent parts were altered by MCP: 477 
ERT (F1.3,15.3 = 0.25, P = 0.784, ηp2 = 0.02) and SIT elicited by TMS (F1.3,15.3 = 2.17, P = 0.136, 478 
ηp2 = 0.15).  479 
 480 
FIGURE 2 HERE 481 
 482 
As shown in Table 3, Mmax was unaffected by MCP (F2,28 = 0.24, P = 0.786, ηp2 = 0.02), nor 483 
was normalized MEP amplitude (Figure 2A, F2,28 = 2.24, P = 0.129, ηp2 = 0.16). However, 484 
SICI was affected (Table 5 and Figure 2B, F1.4, 16.8 = 13.52, P < 0.001, ηp2 = 0.53) with post 485 
hoc tests showing greater inhibition on D21 compared to D2 (mean difference: −10%, P 486 
= 0.048) and D14 (mean difference: −14%, P = 0.001). The pre-stimulus normalised 487 
rmsEMG activity was not different between MCPs (D2: 1.16 ± 0.43, D14: 1.07 ± 0.53, D21: 488 
1.20 ± 0.64% Mmax, F2,28 = 0.31, P = 0.736, ηp2 = 0.025) and neither was the SP (Figure 2C, 489 
Table 5, F2,28 = 0.53, P = 0.594, ηp2 = 0.04). 490 
 491 
FIGURE 3 HERE 492 
 493 
 494 
 495 
 496 
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Fatigability 497 
Time to task failure during the intermittent, isometric, fatiguing task was significantly 498 
affected by MCP (see Figure 3, F1.4, 14.8 = 6.89, P = 0.030, ηp2 = 0.32), with post hoc tests 499 
showing greater TTF on D21 compared to D2 (mean difference: 187 s, P = 0.025).  500 
However, there was no difference between D21 and D14 (mean difference: 135 s, P = 501 
0.103), or D2 and D14 (P = 0.594). The two-way ANOVA (MCP × time) time effect showed 502 
that MVC decreased pre-post exercise (F1,11 = 80.056, P < 0.001, ηp2 = 0.88), as did Qtw.pot 503 
(F1,11 = 123.53, P < 0.001, ηp2 = 0.92), VAMNS (F1,11 = 15.219, P = 0.002, ηp2 = 0.58), and 504 
VATMS (F1,11 = 13.99, P = 0.003, ηp2 = 0.56). SP also increased pre-post exercise (F1,11 = 505 
9.68, P = 0.010, ηp2 = 0.468). The MCP × time interaction effects for the aforementioned 506 
variables that changed pre-post exercise indicated no difference between MCPs (all P ≥ 507 
0.128). The only exception to this was VATMS (F2,22 = 3.48, P = 0.049, ηp2 = 0.24), however, 508 
post hoc tests revealed that the differences were only apparent pre-exercise (as indicated 509 
above), and not post-exercise (P ≥ 0.670). Despite no time effect (P = 0.578), SICI 510 
displayed a MCP × time interaction effect (F1.4, 15.0 = 5.26, P = 0.028, ηp2 = 0.32), however, 511 
the only differences were evident pre-exercise (as indicated above), with no post-512 
exercise difference (P ≥ 0.247). 513 
 514 
TABLE 5 HERE 515 
 516 
All variables measured during the fatiguing tasks (see Figure 4) demonstrated time 517 
effects (P ≤ 0.024), however, only some (MVC, Qtw.pot, VAMNS) demonstrated an absence of 518 
MCP × time interaction effects (P ≥ 0.205). MVC (Figure 4A) decreased progressively from 519 
baseline to 75% TTF (all intervals P ≤ 0.001), however, between 75% and 100% TTF no 520 
further decrease was observed (P = 0.776). A similar pattern was observed with Qtw.pot 521 
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(Figure 4B), with decreases exhibited until 50% TTF (both intervals P ≤ 0.009), however, 522 
between 50-100% TTF Qtw.pot did not further decrease (P ≥ 0.593). VAMNS (Figure 4C) 523 
demonstrated the inverse time course, with no change from 0 to 50% TTF (P ≥ 0.345), 524 
then a progressive decrease from 50 to 100% TTF (P ≤ 0.034). rmsEMG (Figure 4D) and 525 
RPE (Figure 4E) exhibited phase × time interaction effects (P ≤ 0.032). RPE increased 526 
progressively throughout all trials (P ≤ 0.008), however, at 25% TTF RPE was greater on 527 
D21 compared to D14 (+2, P = 0.006), at 50% TTF D21 was greater than D2 (+2, P < 528 
0.001), and at 75% TTF D21 was greater than D2 (+1, P = 0.005). The only significant 529 
increase in rmsEMG was between 25 and 50% TTF (P = 0.003), and despite the phase × 530 
time interaction effect, no post hoc differences between phases were apparent (P ≥ 531 
0.205). 532 
 533 
FIGURE 4 HERE 534 
 535 
DISCUSSION 536 
The present investigation aimed to assess the influence of modulations in female sex 537 
hormones across the eumenorrheic menstrual cycle on neuromuscular function and 538 
fatigability. The data from Study A established repeatability of the measures in a 539 
hormonally-constant female population (mOCP users). Subsequently, Study B showed 540 
that in eumenorrheic females, the hormone-induced changes in neuromuscular function 541 
and fatigability across the menstrual cycle were greater than the associated error from 542 
hormonally-constant females in Study A. Whilst one index of neuromuscular function 543 
(MVC) did not change, modulations in CNS control of muscle contraction were observed. 544 
Specifically, VA was greatest on D14 which was concurrent with an increase in the 545 
concentration of oestrogen. Additionally, parallel to an increase in progesterone, SICI was 546 
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greatest on D21. Time to task failure during the open-ended intermittent, isometric 547 
protocol was greatest on D21 of the cycle. Collectively, the present data suggest that 548 
neuromuscular function and fatigability are modulated by the eumenorrheic menstrual 549 
cycle. 550 
 551 
Maximum strength and voluntary activation across the menstrual cycle 552 
There was no effect of MCP on MVC force. As mentioned, previous data regarding 553 
maximum voluntary strength across the menstrual cycle is equivocal. In agreement with 554 
the present study, multiple studies have shown no effect (24, 40, 46), however, several 555 
studies have shown that strength peaks mid-cycle (49, 53, 64). Previously, discrepancies 556 
such as the time of day (4), or variability in menstrual cycle duration, as well as the chosen 557 
days of the menstrual cycle for testing (27) have been used as explanatory reasons for 558 
this discrepancy. The present study controlled these factors within Study B, by testing at 559 
the same time of day and confirming participants were in the correct phase by serum 560 
hormone analysis, yet no effect of MCP was observed.  561 
 562 
Interestingly, Study B demonstrated changes in VA (assessed by both MNS and TMS) 563 
despite no change in MVC. VAMNS peaked on D14 and VATMS was greater on D14 compared 564 
to D21 (see Figure 1). As Qtw.pot and ERT were not affected by MCP, these changes in VA 565 
were mediated by a decreased SIT amplitude on D14 in response to both motor nerve 566 
and motor cortical stimulation. This could indicate that there was a decrease in the 567 
capacity of the CNS to elicit extra force in response to stimulation. The TMS and MNS 568 
evoked SITs represent the extra force from motor units that the CNS is not able to 569 
voluntarily recruit or discharge at a sufficient rate (68). As acknowledged by Todd et al 570 
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(68), a change in SIT force could be caused by changes in the CNS altering activation of 571 
the motoneuron, therefore changes within the motor cortex could provide an explanation 572 
for the change in VA. An alternative explanation could be the magnitude of the respective 573 
measurement errors of these variables. In Study A, when hormones were controlled, the 574 
CVs of VAMNS (1.7%) and VATMS (3.0%) are lower than the typical error for MVC (5.0%). 575 
Whilst changes seen in the present data set (i.e. the 1.8% increase in VAMNS between D2 576 
– D14, or the 3.1% decrease in VATMS between D14 – D21) were similar to typical error, 577 
it could be the case that the increase in VA was not large enough to elicit a detectable 578 
increase in MVC due to its larger typical error.  Previous studies that have shown VAMNS 579 
not to change have used the CAR equation (40, 46), which is less sensitive to change than 580 
the ITT (50). It is likely therefore, that the magnitude of menstrual cycle effect on VAMNS 581 
and VATMS is marginally greater than the random error associated with the techniques 582 
used to assess it, thus based on current evidence, the true effect is unclear. Also of note is 583 
the MCP × time interaction effect for VATMS, which would indicate that the magnitude of 584 
change from pre-post exercise was different between MCPs. However, this appears to be 585 
driven by the increased VATMS pre-exercise on D14, as there were no differences in post-586 
exercise values. Therefore, it is unlikely that participants experienced a greater degree of 587 
CNS adjustment following exercise during the late-follicular phase (D14). 588 
 589 
Corticospinal and intracortical function across the menstrual cycle 590 
As mentioned, the increase in both measurements of VA on D14 (VAMNS and VATMS) could 591 
represent changes in supraspinal properties altering synaptic drive to the motoneuron 592 
pool across the menstrual cycle (51).  To investigate the state of the corticospinal tract 593 
and motor cortex, the present study employed single- and paired-pulse TMS. No 594 
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menstrual cycle effect was observed on corticospinal excitability, however, intracortical 595 
inhibition was increased on D21. Single pulse MEPs in the resting FDI muscle have 596 
previously been shown not to be affected by oestrogen concentrations (day 1 vs. day 14 597 
of the menstrual cycle, 39), and the present study extends this conclusion to the active 598 
knee extensors, whilst demonstrating that the increase of progesterone concentrations 599 
on D21 is not concurrent with changes in corticospinal excitability. When considering 600 
paired-pulse responses, however, the increase in progesterone concentrations were 601 
concomitant with a ~14% increase in SICI, which when considered with previous 602 
evidence (37, 59), was likely through potentiation of GABAA inhibition. Indeed, GABA 603 
agonist pharmacological interventions (e.g. baclofen and gabapentin) have shown similar 604 
changes (74). The difference between days 14 and 21 demonstrated in Study B (14%) 605 
was double the measurement error of SICI observed in Study A (7%), however, there was 606 
no difference between D2 and D14 (difference = 4%). Interestingly, SICI followed a 607 
similar pattern to the E:P ratio (see Table 4), with the only significant change 608 
demonstrated on D21 concurrent to a decrease in the E:P ratio. Furthermore, the MCP × 609 
time interaction effect for SICI in Study B would suggest that intracortical inhibition is 610 
differentially modulated by exercise throughout the menstrual cycle. Whilst this is a 611 
concept that has been postulated before (23), and the present data appears to show this 612 
phenomenon, the interaction should be treated with caution as the post-exercise 613 
reliability of SICI in Study A was poor. A significant bias was observed (P = 0.031), with a 614 
poor ICC value (0.42), thus, a conclusion regarding MCP specific changes in intracortical 615 
inhibition following exercise cannot be confidently made using the present data. 616 
 617 
The TMS SP, thought to partly reflect GABAB inhibitory mechanisms (14) was not affected 618 
by MCP, supporting previous data recorded in the FDI muscle (33). However, the 619 
27 
 
conclusion that the menstrual cycle affects only GABAA neurotransmission cannot be 620 
made with the current data, as Yacyshyn et al. (73) showed that the SP has a large spinal 621 
contribution. Additionally, glutamatergic intracortical facilitation (ICF) was not 622 
measured in the present study, but has previously been shown to be affected by the 623 
menstrual cycle, with augmented ICF demonstrated mid-cycle (56, 57). Whilst the causal 624 
link between intracortical function and voluntary activation is under researched, it is 625 
possible that the adjustments of intracortical circuitry altered the capacity of TMS and 626 
MNS to evoke a SIT. For instance, if intracortical excitability was greatest on D14, there 627 
may have been a ‘ceiling effect’, meaning the stimulations were not able to induce 628 
additional excitation in the motor cortex, thus, innervating fewer additive motor units 629 
during MVCs, and evoking a smaller SIT, and the contrary occurring on D21, when 630 
inhibition was greatest. The modulation of neurotransmitters has previously shown to 631 
affect VA, with pharmacological increases in noradrenaline (44) and serotonin (42) 632 
resulting in a ~1-2% increase in VA. Indeed the effects of serotonin have been shown to 633 
be augmented by oestrogen (3), and inhibited by progesterone (34). Therefore, it is 634 
possible that the modulation of inhibitory and facilitatory intracortical circuitry across 635 
the menstrual cycle might collectively contribute to the changes in VAMNS and VATMS. 636 
 637 
Fatigability across the menstrual cycle 638 
Fatigability, as measured by the TTF of the open-ended fatiguing protocol, was lowest on 639 
D21 (i.e. greatest TTF), thus supporting the findings of Sarwar et al. (53), who showed 640 
that fatigue index was lowest in the luteal phase during a three-minute intermittent 641 
involuntary contraction protocol. The present data, however, contradicts Janse de Jonge 642 
et al. (40), who showed no effect of MCP during voluntary or electrically evoked fatiguing 643 
protocols performed with the knee extensors. The differences between tasks could 644 
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explain these discrepancies. The voluntary task used by Janse de Jonge et al. (44) involved 645 
both dynamic knee extension and flexion, rather than a single muscle group. This 646 
anisometric, multi-muscle group exercise likely elicits a different pattern of sensory 647 
afferent feedback (30), and was not open-ended like the present study, which could 648 
explain the discrepancies in fatigability. The same reasons might also apply to why the 649 
findings of DiBrezzo et al. (21) are inconsistent with the present study, who similarly 650 
demonstrated no menstrual cycle effect on fatigue during a set amount of dynamic 651 
contractions. Thus, the task employed in the present study likely permitted a greater 652 
degree of fatigue to develop, allowing the aforementioned MCP differences to be 653 
discerned. 654 
 655 
As widely acknowledged, fatigability has both physiological and perceptual components 656 
that interact to determine exercise tolerance (26, 66). The fatiguing task in the present 657 
study involved high intensity (60% MVC) intermittent, isometric contractions, which 658 
were assumed to be far greater than the critical torque (~30% MVC [12]), and limited by 659 
decrements in neuromuscular adjustments (1, 11). With no MCP x time interaction effects 660 
displayed for neuromuscular variables (MVC, Qtw.pot, and VA), the degree of pre-post 661 
exercise adjustment was not different between menstrual cycle phases. Accordingly, one 662 
hypothesis for why TTF was longer on D21 could be the influence of neurotransmitter 663 
systems on perceptions of fatigue. The present study measured GABAergic inhibition and 664 
demonstrated a large increase in SICI on D21 (Figure 2B), and it has previously been 665 
shown that GABA can have anti-nociceptive properties (25) acting as an analgesic (41). 666 
Indeed, it has recently been postulated that “luteal analgesia” occurs in eumenorrheic 667 
females when progesterone is elevated, where the affective response to nociceptive pain 668 
is reduced due to alterations in functional connectivity in the emotional regulation 669 
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network (69). Thus, it could be possible that the analgesic effects of enhanced GABAergic 670 
neurotransmission permitted participants to continue exercising for a longer period due 671 
to a lower perception of pain. However, more evidence is needed to explore the effects of 672 
GABAergic inhibition on exercise-induced fatigue. 673 
 674 
Further Considerations 675 
In Study B it would appear that there was substantial between-subject variation in 676 
neuromuscular function and the changes across the menstrual cycle (Figures 1-3). 677 
Potential explanations for this could be the large standard deviations in hormone 678 
concentrations at each time point (Table 4), which has been reported in previous 679 
investigations (55). Additionally, inter-individual differences in hormone receptor 680 
numbers and sensitivity could contribute to the variation in changes across the menstrual 681 
cycle. In muscle tissue (22), expression of sex hormone receptors is altered by changing 682 
hormonal environments, which could conceivably occur in neuronal tissues such as the 683 
motor cortex, however the present data cannot answer this research question. 684 
 685 
Whilst serum hormones were quantified for the eumenorrheic females in Study B, the 686 
mOCP users’ serum hormone concentrations were not quantified in Study A. These data 687 
would have provided useful information about the measurement error of the sample, 688 
however individual ‘meaningful’ changes might differ between participants in order to 689 
achieve ovulation. 690 
 691 
Conclusion 692 
The present investigation demonstrated that when neuro-active hormones are constant, 693 
females demonstrate stable neuromuscular function (Study A). In contrast, when 694 
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eumenorrheic females were tested at three distinct phases of the menstrual cycle (Study 695 
B), the changing hormonal environment coincided with large changes in CNS function, 696 
which affected aspects of motor performance. Specifically, oestrogen had neuro-697 
excitatory effects that were associated with an increase in VA on D14, whereas 698 
progesterone’s neuro-inhibitory effects was concurrent with an increased intracortical 699 
inhibition and decreased VA. Additionally, fatigability was modulated by MCP, with the 700 
greatest TTF seen on D21, concurrent with an increase in progesterone. Thus, the 701 
menstrual cycle elicits changes in neuromuscular function and fatigability in locomotor 702 
muscle of eumenorrheic females.  703 
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Tables 907 
Table 1: Monophasic combined oral contraceptive pills (mOCPs) taken by participants in Study 908 
A. 909 
OCP brand No. Participants 
Synthetic 
Estrogen 
Dosage 
(µg) 
Synthetic 
Progestin 
Dosage 
(µg) 
Rigevidon® 6 Ethinylestradiol 30 Levonorgestrel 150 
Cilest® 3 Ethinylestradiol 35 Norgestimate 250 
Yasmin® 2 Ethinylestradiol 30 Drospirenone 300 
Gedarel® 1 Ethinylestradiol 20 Desogestrel 150 
Gedarel® 1 Ethinylestradiol 30 Desogestrel 150 
Microgynon® 1 Ethinylestradiol 30 Levonorgestrel 150 
Levest® 1 Ethinylestradiol 30 Levonorgestrel 150 
 910 
 911 
 912 
 913 
Table 2: Reliability data for mechanical variables pre- and post-exercise in Study A. Pre-post 914 
change (Δ) is presented when a significant (P < 0.05) change was observed. 915 
Measure   Visit 1 Visit 2 P  Bias TE CV (%) ICC (95% CI) 
MVC Pre 502 ± 90 511 ± 103 0.314  -9 23 4.5 0.96 (0.89 - 0.98) 
(N) Post  375 ± 93 383 ± 81 0.356  -8 24 6.2 0.94 (0.82 - 0.98) 
 Δ -128 ± 43 -128 ± 51 0.972  0 30 23.9 0.62 (0.18 - 0.85) 
     
Qtw.pot Pre 168 ± 27 170 ± 22 0.589  -2 9 5.0 0.90 (0.72 - 0.96) 
(N) Post 110 ± 22 110 ± 21 0.942  0 11 10.4 0.75 (0.40 - 0.91) 
 Δ -58 ± 29 -61 ± 21 0.643  -2 12 19.7 0.81 (0.53 - 0.93) 
     
ERT Pre 121 ± 38 118 ± 34 0.689  3 15 12.5 0.85 (0.62 - 0.95) 
(N) Post  94 ± 30 91 ± 27 0.605  3 14 14.9 0.79 (0.48 - 0.92) 
 Δ -27 ± 25 -27 ± 28 0.943  0 17 62.7 0.63 (0.20 - 0.86) 
     
VATMS Pre 94.3 ± 3.3 94.8 ± 2.9 0.679  -0.5 2.8 3.0 - 
(%) Post  82.3 ± 11.1 83.9 ± 10.4 0.406  -1.6 5.1 6.1 - 
 Δ -12.0 ± 11.2 -10.9 ± 9.6 0.573  1.1 5.2 45.4 0.78 (0.46 - 0.92) 
     
VAMNS Pre 93.6 ± 3.0 93.7 ± 3.2 0.834  -0.1 1.6 1.7 - 
(%) Post  84.5 ± 7.2 85.8 ± 6.7 0.942  -1.3 3.6 4.2 - 
 Δ -9.1 ± 6.0 -7.9 ± 6.1 0.390  1.2 3.7 43.2 0.66 (0.24 - 0.87) 
     
TTF  560 ± 275 603 ± 357 0.338 -43 117 20.0 0.88 (0.69 - 0.96)
(s)    
CV: Coefficient of variation; ICC: Intraclass correlation coefficient; MVC: Maximum voluntary contraction; 
Qtw.pot: Potentiated quadriceps twitch; ERT: Estimated resting twitch; VATMS: Voluntary activation assessed 
with TMS; VAMNS: Voluntary activation assessed with MNS; TE: Typical error; TTF: Time to task failure
38 
 
Table 3: Reliability values for electromyographical data pre- and post-exercise. Pre-post change 916 
(Δ) is presented when a significant (P < 0.05) change was observed. 917 
Measure   Visit 1 Visit 2 P Bias TE CV (%) ICC (95% CI)
MEP/Mmax Pre 22.4 ± 12.0 19.8 ± 10.5 0.291 2.6 6.40 30.1 0.71 (0.34 - 0.89)
(%) Post  17.8 ± 9.0 16.9 ± 10.1 0.677 0.9 5.4 31.0 0.72 (0.34 - 0.90)
 Δ - - - - - - - 
    
SICI  Pre 78.7 ± 15.0 82.9 ± 13.5 0.148 -4.2 7.4 9.2 0.75 (0.42 - 0.91)
(%)  Post  75.3 ± 13.3 84.3 ± 13.3 0.031 -9.1 10.4 13.0 0.42 (0.00 – 0.75)
 Δ - - - - - - - 
    
Mmax Pre 2.96 ± 1.13 3.08 ± 1.28 0.507 -0.12 0.48 15.9 0.86 (0.64 – 0.92)
(mV) Post  2.74 ± 1.01 2.88 ± 1.03 0.466 -0.14 0.50 17.8 0.79 (0.47 - 0.92)
 Δ - - - - - - - 
    
SP Pre 187 ± 45 190 ± 50 0.791 -3 31 16.4 0.60 (0.24 - 0.82)
(ms) Post  201 ± 56 202 ± 46 0.947 -8 37 19.2 0.63 (0.19 - 0.86)
  Δ 14 ± 29 12 ± 23 0.815 2 19.8 155.1 0.44 (0.00 - 0.77) 
CV: Coefficient of variation; ICC: Intraclass correlation coefficient; MEP: Motor evoked potential, MVC: maximum voluntary 
contraction, SICI: Short interval cortical inhibition, Mmax: maximum compound action potential; TE: Typical error
 918 
 919 
 920 
 921 
 922 
 923 
 924 
 925 
Table 4: Group average concentrations for 17-β oestradiol and progesterone across the three 926 
tested phases of the menstrual cycle. * = greater than d2, # = greater than d14, † = greater than 927 
d21 (all P < 0.05). 928 
 Day 2 Day 14 Day 21 
17-β Oestradiol 
(pg.ml-1) 
 
248 ± 129 328 ± 160* 341 ± 186* 
 
Progesterone 
(ng.ml-1) 
 
1.27 ± 0.50 1.38 ± 0.69 4.41 ± 4.60* # 
E:P ratio 0.20 ± 0.13 0.28 ± 0.18 0.12 ± 0.10* # 
 929 
 930 
39 
 
Table 5: Variables assessed throughout the pre- and post-exercise testing battery across the menstrual cycle. P values from the baseline ANOVA (1 × 931 
3 repeated measures), and the pre-post exercise ANOVA (2 × 3 repeated measures) are reported. When a significant effect of exercise was found, the 932 
∆ in a variable from pre-post exercise was reported. * =greater than day 2, # = greater than day 14, † = greater than day 21. 933 
  Day 2  Day 14 Day 21 MCP effect Pre-post exercise MCP × Exercise 
    Pre Post ∆  Pre Post ∆ Pre Post ∆ 1×3 ANOVA 2×3 ANOVA 2×3 ANOVA 
MVC (N)  457 ± 79 344 ± 59 −25%  454 ± 78 337 ± 67 −26% 460 ± 87 355 ± 93 −24% 0.790 <0.001 0.236 
       
SITMNS (N)  9 ± 5# 11 ± 7 -  7 ± 4 10 ± 8 - 8 ± 4 11 ± 6 - 0.040 0.069 0.452 
       
Qtw.pot (N)  148 ± 20 95 ± 24 −36%  150 ± 20 91 ± 22 −39% 151 ± 23 94 ± 26 −38% 0.782 <0.001 0.634 
       
VAMNS (%)  93.4 ± 2.8 88.4 ± 8.8 −6%  95.3 ± 1.9* 87.9 ± 6.9 −8% 94.3 ± 2.2 88.0 ± 5.6 −7% 0.001 0.002 0.303 
       
SITTMS (N)  6 ± 2 10 ± 8 67%  5 ± 3 9 ± 7 80% 7 ± 6 10 ± 9 43% 0.136 0.028 0.292 
       
ERT (N)  94 ± 43 74 ± 37 −35%  96 ± 39 64 ± 60 −40% 93 ± 43 70 ± 36 −35% 0.784 0.001 0.128 
       
VATMS (%)  93.2 ± 2.8 87.5 ± 8.5 −6%  95.7 ± 2.4† 84.3 ± 9.4 −12% 92.6 ± 3.2 86.7 ± 9.7 −7% 0.008 0.003 0.049 
       
MEP/Mmax (%) 17 ± 5 17 ± 9 -  22 ± 7 18 ± 9 - 18 ± 10 15 ± 8 - 0.129 0.278 0.485 
       
SICI (%)  77 ± 11* 84 ± 14 -  82 ± 10* 74 ± 22 - 67 ± 12 75 ± 19 - 0.001 0.578 0.028 
       
SP (ms)  160 ± 42 176 ± 49 12%  173 ± 70 176 ± 54 2% 174 ± 48 176 ± 49 3% 0.594 0.010 0.360 
       
Mmax (mV)  4.05 ± 2.19 3.93 ± 2.27 -  4.39 ± 1.88 4.06 ± 2.12 - 4.30 ± 2.50 3.80 ± 2.28 - 0.786 0.087 0.436 
       
TTF (s)   519 ± 164  571 ± 179 706 ± 262* 0.030 - - 
MVC: maximum voluntary contraction, SITMNS: superimposed twitch elicited by motor nerve stimulation; Qtw.pot: potentiated quadriceps twitch; VAMNS: voluntary activation assessed with motor nerve stimulation; 
SITTMS: superimposed twitch elicited by transcranial magnetic stimulation; ERT: estimated resting twitch; VATMS: voluntary activation assessed with TMS; MEP/Mmax: corticospinal excitability; SICI: short-interval 
cortical inhibition; SP: TMS evoked silent period; Mmax: maximum compound muscle action potential; TTF: time to task failure. 
 934 
 935 
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 936 
Figure Legends 937 
 938 
Figure 1: Baseline neuromuscular measures across the three timepoints. Panel A: 939 
maximum voluntary contraction; Panel B: potentiated twitch force; Panel C: voluntary 940 
activation assessed with motor nerve stimulation; Panel D: voluntary activation assessed 941 
with transcranial magnetic stimulation; Panel E: superimposed motor nerve stimulation 942 
evoked twitch during a maximum voluntary contraction; Panel F: superimposed 943 
transcranial magnetic stimulation evoked twitch during a maximum voluntary 944 
contraction. Individual data are shown with mean data overlaid as the filled symbols and 945 
connecting line.  946 
 947 
Figure 2: Transcranial magnetic stimulation evoked responses across the three testing 948 
time points. Panel A: corticospinal excitability; Panel B: short interval cortical inhibition; 949 
Panel C: TMS evoked silent period. Individual data are shown with mean data overlaid as 950 
the filled symbols and connecting line. 951 
 952 
Figure 3: Time to task failure during the submaximal intermittent isometric fatiguing 953 
task at the three testing time points. Individual data are shown with mean data overlaid 954 
as the filled symbols and connecting line. 955 
 956 
 957 
Figure 4: Neuromuscular variables assessed at 25, 50, 75 and 100% TTF throughout the 958 
fatiguing tasks in each MCP. Panel A: maximum voluntary contraction; B: potentiated 959 
quadriceps twitch; C: voluntary activation assessed with motor nerve stimulation; D: 960 
root-mean-squared EMG; E: rating of perceived exertion. Data are means with the 961 
standard deviation shown in panels A-D for the final point. Data are displayed as % 962 
baseline, although  statistical analyses were performed on absolute data. Statistical 963 
differences (P < 0.05) are depicted by a: significantly difference between baseline-25% 964 
TTF; b: significant difference between 25-50% TTF; c: significant difference between 965 
50-75% TTF; d: significant difference between 75-100% TTF; *: significant difference 966 
between D21-D14; #: significant difference between D21-D2. 967 
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